| Interpreting population pharmacokinetic‐pharmacodynamic analyses–a clinical viewpoint SB Duffull, DFB Wright, HR Winter British journal of clinical pharmacology 71 (6), 807-814, 2011 | 145 | 2011 |
| Understanding the time course of pharmacological effect: a PKPD approach DFB Wright, HR Winter, SB Duffull British journal of clinical pharmacology 71 (6), 815-823, 2011 | 106 | 2011 |
| Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ... Annual review of pharmacology and toxicology 61, 225-245, 2021 | 104 | 2021 |
| Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout LK Stamp, TR Merriman, ML Barclay, JA Singh, RL Roberts, DFB Wright, ... Seminars in arthritis and rheumatism 44 (2), 170-174, 2014 | 67 | 2014 |
| Predicting allopurinol response in patients with gout DFB Wright, SB Duffull, TR Merriman, N Dalbeth, ML Barclay, LK Stamp British journal of clinical pharmacology 81 (2), 277-289, 2016 | 61 | 2016 |
| A Bayesian dose-individualization method for warfarin DFB Wright, SB Duffull Clinical pharmacokinetics 52, 59-68, 2013 | 61 | 2013 |
| Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C PKL Chin, DFB Wright, M Zhang, MC Wallace, RL Roberts, DM Patterson, ... Drugs in R&D 14, 113-123, 2014 | 57 | 2014 |
| Clinical decision-making: an essential skill for 21st century pharmacy practice DFB Wright, MG Anakin, SB Duffull Research in Social and Administrative Pharmacy 15 (5), 600-606, 2019 | 49 | 2019 |
| The population pharmacokinetics of allopurinol and oxypurinol in patients with gout DFB Wright, LK Stamp, TR Merriman, ML Barclay, SB Duffull, ... European journal of clinical pharmacology 69, 1411-1421, 2013 | 46 | 2013 |
| The association between metformin therapy and lactic acidosis IHS Kuan, RL Savage, SB Duffull, RJ Walker, DFB Wright Drug Safety 42, 1449-1469, 2019 | 38 | 2019 |
| A philosophical framework for pharmacy in the 21st century guided by ethical principles SB Duffull, DFB Wright, CA Marra, MG Anakin Research in Social and Administrative Pharmacy 14 (3), 309-316, 2018 | 38 | 2018 |
| Development of a bayesian forecasting method for warfarin dose individualisation DFB Wright, SB Duffull Pharmaceutical research 28, 1100-1111, 2011 | 38 | 2011 |
| A proposal for dose‐adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time PKL Chin, DFB Wright, DM Patterson, MP Doogue, EJ Begg British journal of clinical pharmacology 78 (3), 599-609, 2014 | 35 | 2014 |
| Warfarin dosing algorithms underpredict dose requirements in patients requiring≥ 7 mg daily: A systematic review and meta‐analysis SM Saffian, SB Duffull, DFB Wright Clinical Pharmacology & Therapeutics 102 (2), 297-304, 2017 | 32 | 2017 |
| A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments. EH Baker, D Gnjidic, CMJ Kirkpatrick, M Pirmohamed, DFB Wright, ... Br J Clin Pharmacol 87 (3), 707-711, 2021 | 26 | 2021 |
| ‘Massive’metformin overdose AL Chiew, DFB Wright, NM Dobos, K McArdle, AA Mostafa, A Newth, ... British journal of clinical pharmacology 84 (12), 2923-2927, 2018 | 26 | 2018 |
| Coagulation assays and plasma fibrinogen concentrations in real‐world patients with atrial fibrillation treated with dabigatran PKL Chin, DM Patterson, M Zhang, BP Jensen, DFB Wright, ML Barclay, ... British journal of clinical pharmacology 78 (3), 630-638, 2014 | 26 | 2014 |
| What do we learn from repeated population analyses? SB Duffull, DFB Wright British Journal of Clinical Pharmacology 79 (1), 40-47, 2015 | 24 | 2015 |
| Methods for predicting warfarin dose requirements SM Saffian, DFB Wright, RL Roberts, SB Duffull Therapeutic drug monitoring 37 (4), 531-538, 2015 | 22 | 2015 |
| Dabigatran: rational dose individualisation and monitoring guidance is needed SB Duffull, DFB Wright, HS Al-Sallami, PJ Zufferey, JM Faed The New Zealand Medical Journal (Online) 125 (1357), 2012 | 21 | 2012 |
Murray BarclayClinical Professor of Medicine, Christchurch Hospital and University of OtagoVerified email at cdhb.health.nz
